Cargando…

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

INTRODUCTION: In recent years, immune checkpoint inhibitors (ICIs) have attracted widespread attention and made breakthroughs in progress towards the treatment of various cancers. However, ICI therapy is selective, and its effects on many patients are not ideal. It is therefore critical to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Anqi, Gu, Tianqi, Hu, Xigang, Zhang, Jian, Luo, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192307/ https://www.ncbi.nlm.nih.gov/pubmed/35707003 http://dx.doi.org/10.1155/2022/8179799

Ejemplares similares

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma
por: Shen, Kai, et al.
Publicado: (2021)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma
por: Wu, Dabin, et al.
Publicado: (2022)

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
por: Lavoie, Jean-Michel, et al.
Publicado: (2022)

ZNF692 promotes colon adenocarcinoma cell growth and metastasis by activating the PI3K/AKT pathway
por: Xing, Yanwei, et al.
Publicado: (2019)

Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma
por: Jiang, Fengqi, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Comprehensive Analysis of the Expression, Prognostic Value, and Immune Infiltration Activities of GABRD in Colon Adenocarcinoma
por: Huang, Fakun, et al.
Publicado: (2023)

TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
por: Qiu, Tianzhu, et al.
Publicado: (2022)

High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity
por: Huang, Xinkun, et al.
Publicado: (2022)

Francisella Subverts Innate Immune Signaling: Focus On PI3K/Akt
por: Cremer, Thomas John, et al.
Publicado: (2011)

Construction of prognostic predictor by comprehensive analyzing alternative splicing events for colon adenocarcinoma
por: Qu, Yaqi, et al.
Publicado: (2020)

MicroRNA-708 targeting ZNF549 regulates colon adenocarcinoma development through PI3K/AKt pathway
por: Zhao, Zhidong, et al.
Publicado: (2020)

Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma
por: Cui, Guoliang, et al.
Publicado: (2022)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Zhu, Shaoming, et al.
Publicado: (2021)

The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
por: Zhang, Zhizhu, et al.
Publicado: (2021)

Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
por: Dulal, Dharmindra, et al.
Publicado: (2023)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study
por: Hu, Fang, et al.
Publicado: (2022)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials
por: Fujiwara, Yutaka, et al.
Publicado: (2020)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
por: Lin, Anqi, et al.
Publicado: (2022)

Gene mutations in the PI3K/Akt signaling pathway were related to immune thrombocytopenia pathogenesis
por: Ruan, Jing-Shu, et al.
Publicado: (2023)

Comprehensive Analyses of Stromal-Immune Score-Related Competing Endogenous RNA Networks In Colon Adenocarcinoma
por: Tong, Yalin, et al.
Publicado: (2022)

A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
por: Chen, Yusheng, et al.
Publicado: (2023)

Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma
por: Xu, Zhiquan, et al.
Publicado: (2022)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
por: Wang, Zhenghang, et al.
Publicado: (2022)

Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
por: Zhang, Zhizhu, et al.
Publicado: (2022)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
por: Biniakewitz, Matthew D., et al.
Publicado: (2020)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
por: Elia, Angela Rita, et al.
Publicado: (2018)

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
por: Guo, Dina, et al.
Publicado: (2020)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bpivm9acjuvoglh7hj77dr3qo2